http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2648521-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce02804c597add535d0781d73ab2d2f1
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-557
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-557
filingDate 2013-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cb3209fb0027fd4cc1588fa930a5a1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c86f216b37e56896390fef4c15932ab5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_969ea5b3d97bb6ad2f1803a6e8b12daf
publicationDate 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2648521-C2
titleOfInvention Immunoassay-based determination of in-solution binding kinetics
abstract FIELD: pharmaceuticals. n SUBSTANCE: invention relates to a method for determining the binding affinity of a drug to its target, comprising the following steps: determining the fraction of free drug or free target in a sample, comprising a drug, target and non-covalent drug-target-complexes in the drug concentration range at a constant target concentration, where the free drug fraction remains constant, by determining, based on the result of an immunoassay, the fraction of free drug in a drug-containing sample, target and drug-target-complexes, for at least two different drug ratios: the target in the sample and, if a certain fraction of the free drug is not comparable for all used ratios of the drug: the target, then the ratio of the drug: the target in the sample is reduced, and the sample is reanalyzed by the same immunoassay, or based on the result of the immunoassay, of the proportion of the free target in the sample, containing the drug and target-drug-complexes, for at least two different drug-target ratios: the target in the sample, and, if a certain fraction of the free target is not comparable for all used ratios of the drug: target, then the drug: target ratio in the sample is increased and the sample is reanalyzed by the same immunoassay, and the calculation based on the proportion of free drug or calculation based on the proportion of the free target, determined at the previous stage, the affinity of the binding of the drug to its target, where "comparable" means the relative difference (% of differences) of two specified values of less than 100 %, and "incomparable" means the relative difference (% difference) of two defined values greater than 100 % where % is difference, calculated according to the following formula % dif. = [(highest value) – (lowest value)] / (arithmetic mean), where to calculate the binding affinity (K D ) apply the following equation: K D = (free drug share) * (target concentration [nM] / (1 – free drug fraction). n EFFECT: technical result of the invention lies in the fact that the determination of the affinity of the binding agent and its ligand in the samples can be carried out using very limited (small) number of measurements (samples), which reduces the complexity of the method and improves its accuracy. n 12 cl, 6 ex, 11 dwg
priorityDate 2012-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011094445-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67964
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID11309
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15478
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP16612
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N5
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419520973
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID83785
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26617
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID407217
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99PS1
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67860
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7422
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04412
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID463415
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9MYV3
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13649
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GKR0
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF6QDM7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15692
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1956
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396494
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID378478
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID11309
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395909
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A3Q2TVI4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP22629
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49151
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP50412
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCH0ZCS4
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414865888
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67965
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15691
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ00731
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID558154
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID22339
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281572
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24329
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9702
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30682
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83906
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403802
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID404306

Total number of triples: 60.